Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Clinical Roundup
NCI Trials
NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Trump 2016: A look back at the 45th president’s impact on oncology
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Rooting out the “illegal and immoral discrimination” of DEI is the first order of business for Trump